Synthesis and evaluation of 4-[18F]fluorothalidomide for the in vivo studies of angiogenesis
Authors:
- Dong Hyun KimDKDong Hyun Kim
- Yearn Seong ChoeYCYearn Seong Choe
- Kyoung-Ho JungKJKyoung-Ho Jung
- Kyung-Han LeeKLKyung-Han Lee
- Yong ChoiYCYong Choi
- Byung-Tae KimBKByung-Tae Kim
- 28 February 2006
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (2) , 255-262
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Use of angiogenesis inhibitors in tumour treatmentEuropean Journal of Cancer, 2005
- Thalidomide in solid tumours: the resurrection of an old drugEuropean Journal of Cancer, 2004
- Thalidomide in cancer medicineAnnals of Oncology, 2004
- Angiogenesis in human cancer: implications in cancer therapyEuropean Journal of Internal Medicine, 2003
- Angiogenesis: regulators and clinical applicationsBiochemical Pharmacology, 2001
- Angiogenesis in cancer and other diseasesNature, 2000
- Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drugBritish Journal of Haematology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971